Form 4: Reviva Pharma Director Granted Stock Options

Reviva Pharmaceuticals Holdings, Inc. director Purav Patel was granted 8,200 stock options with an exercise price of $0.5848, vesting one year from the grant date.

Summary

• Purav Patel, a Director of Reviva Pharmaceuticals Holdings, Inc. (RVPH), was granted 8,200 stock options.
• The options have an exercise price of $0.5848 per share.
• The grant date for these options was December 18, 2025.
• The options will vest 100% on the one-year anniversary of the grant date, specifically December 18, 2026.
• Vesting is contingent upon Purav Patel remaining a director of the Company through the vesting date.
• The options expire on December 17, 2035.
• This award was made under the terms of the Company's 2020 Equity Incentive Plan.
• Following this transaction, Purav Patel beneficially owns 8,200 derivative securities.

Sentiment

Score: 7

Explanation: The filing reports a routine compensation event for a director, which is generally positive for aligning interests but does not indicate a significant change in the company's operational or financial outlook. It's a standard governance action.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The options were granted in accordance with the Company's established 2020 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Risks

• The vesting of the options is conditional on the reporting person remaining a director of the Company through the one-year anniversary of the grant date, posing a retention risk for the director to fully realize the benefit.

Future Outlook

The grant of these stock options is a forward-looking incentive designed to retain the director and align their long-term interests with the company's performance, with the full benefit contingent on continued service through the vesting date.

Management Comments

• The option award was made in accordance with the terms of the 2020 Equity Incentive Plan of Reviva Pharmaceuticals Holdings, Inc.
• The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages to attract, retain, and motivate experienced board members. This aligns director interests with shareholder value creation over the long term.

Comparison to Industry Standards

• Equity compensation for directors, such as stock options, is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to foster alignment with shareholder interests.
• The vesting schedule of one year is a common approach for director option grants, balancing immediate incentive with a retention component.
• The exercise price being set at the closing price on the grant date is a typical and compliant method for option pricing under most equity incentive plans.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value creation, potentially leading to more focused governance and strategic decisions.
• Employees: While this specific grant is for a director, the existence and utilization of an equity incentive plan can signal a broader commitment to performance-based compensation, which may positively influence employee morale and retention if similar plans are available to them.

Next Steps

• The options will vest on December 18, 2026, provided the director remains with the company.
• The director may choose to exercise the options at any point between the vesting date and the expiration date of December 17, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation package. While it aligns the director's interests with shareholders, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard governance and compensation event.

Keywords

RVPH, stock options, director compensation, equity incentive plan, insider transaction, Form 4, Reviva Pharmaceuticals